Step III Pain Control with Oral Morphine in Terminally Sick Cancer Patients by M Ashraf Teli
JK SCIENCE
112 Vol. 10 No. 3, July-September 2008
 REVIEW ARTICLE
From the Department of Radiation Oncology, SKIMS, Srinagar (J&K)
Correspondence to : Dr.M.Ashraf Teli, Additional Professor, Radiation Oncology, SKIMS, Srinagar (J&K)
Step III Pain Control with Oral Morphine
in Terminally Sick Cancer Patients
M Ashraf Teli
Introduction
Terminal medical illness is a disease status which has
progressed beyond the stage at which treatment aimed
at remission is feasible. This state may exist (persist) for
variable period of time and majority of cancer patients
suffer from pain during this period.  Though, impending
death is foreign to our goals, frame-work and training yet
the responsibilities and obligations of the clinician do not
end when physical disease eludes cure (1). Data from
several prospective surveys suggest that 70-90% of
patients with cancer pain could attain adequate relief if
guidelines of WHO (WHO ladder) and/or US agency
for Health Care Policy and Research are followed with
judicious use of  opioids/oral morphine (2,3). The hard
fact is that more than 40% patients with pain are under-
treated (4,5), which usually leads to development of
chronic pain syndrome manifesting in; Depression,
Dependency,  Disability,Disuse, Drug misuse Drug abuse,
Doctor shopping/Hypochondriasis.
Pain has been regarded as a form of punishment for
sinful activity (6,7). Infact, the word pain comes from
the Latin word”poena” meaning “punishment”(8). Pain
is a common feared symptom in cancer patients. It occurs
in 50-80% of patients with advanced cancer
(9-11).Terminally sick patients often report the fear of
intractable pain and loosing self-control more than they
fear dying. They frequently express the desire to have
an open dialogue with medical faculty about pain and
want to be involved fully, with self control, in planning
their pain management (12). Though reassurance is
helpful, Collusion and false hope must be avoided at all
costs in order to preserve trust. Because, having promised
to keep the patient relatively pain-free, it is paramount to
meet this promise. Attempt and treatment goal should
be prevention of pain because, it is easier to check than
to relieve pain in cancer and drug(s) should be prescribed
on a prophylactic basis with no other consideration than
maintaining the best possible quality of life; adding life to
remaining days rather than adding merely days to life of
a terminally sick cancer patient (13).
We, at our Institute started using oral morphine in
terminally sick cancer patients with pain for last 4-5
years. This review is a gist of  experience of various
authors and our own  to encourage the clinicians.
Procedures for pain management in terminal Sickness:-
Cancer pain can be controlled in most patients by
relatively cheaper oral drug(s) after a detailed assessment
of pain, using different pain scoring scales(Visual
Analogue, Numerical scale, etc), and analysis of the
suitability of analgesic(s) (14).
Approch to Terminally Sick Cancer Patient
a) Establish the cause of the pain which may be due
to cancer or  due to treatment related side effects
make a full assessment of all contributing factors.
Differentiate between acute, chronic, nociceptive
and neuropathic pain.
b) Try to use minimum number of drugs in the most
acceptable  form. Assess prior treatment as a
guideline to future treatment
c)  Use of WHO analgesic ladder to guide systematic
pain relief  is recommended but one has to beJK SCIENCE
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vigilant as other treatments (surgery, nerve blocks,
radiotherapy etc) may also contribute in alleviating
the pain (15,16)
d)  Choice of drug(s) should be based on the severity
of pain Step up to higher step when lower step
analgesics have failed.( Figure-1)
e)  Use drug(s) by the mouth; by the clock; by the
ladder; for the individual with attention to detail
f)  Adjuvant drugs i.e  anxiolytics may be added which
augments the analgesic effect.
g) Prescribe not only to cover continuous background
pain felt by the patient but also for breakthrough
that occurs with everyday activities such as walking
or omitting a prescribed dose . The aim is keep the
patient pain-free both when sitting at home but also
when undertaking normal daily activities.
h) Regular review is essential to ensure that treatment
goals are being met and side-effects avoided
Strong opioids ( Step III pain control ) - Oral morphine
Opioids have been consistently under-used in the
treatment of cancer pain because the general population
,physicians, and paramedical staff share many of the
common myths which include;
a)  Opioids cause addiction
b)  Opioids cause frequent respiratory depression
c)  Opioids decrease survival
d)  Physical dependence  and addiction is same
 Counter Common Myths & Misunderstandings
a) Under normal prescription opiods are not normally
addictive. Dose reduction of morphine is possible if
other measures counter the cause of the pain.
b)  Respiratory depression is not usually a common problem
with oral morphine. Pain tends to counter this effect.
c)  At the correct dose patients can continue with normal
activities. Initial sedation may occur but, it usually
settles within 48 hours
d) Patients are normally maintained for several weeks on
a constant dose and significant tolerance to morphine
does not usually develop (17,18)
Dose Titration
 “There is no standard dose of morphine. The dose
needs adjustment against effect for each patient
individually with starting dose determined roughly by
previous analgesic treatment”.
Guideline for Dose Titration
a)  For a navie patient starting dose for opioid is usually
5-10mgs.adminstered at 4 hourly interval .We,at our
centre, have used 10 mgs 6 hourly schedule in our
patients with good pain relief and most of these
patients stayed pain free for an appreciable length
of  time before dose escalation or frequency
reduction to 4 hourly schedule.We have  found 6
hrly schedule most acceptable  amongst our  patient
population.
b)  For ‘breakthrough pain’ extra doses of the same
size is  administered.
c)  Many Hospice centres give double  dose at bedtime
to avoid waking-up from sleep.
d)  After 24 hours total the previous day’s intake 4
hourly/6  hourly dose requirement is calculated thus,
adjusting the regular dose needed.
e)  If oral route is not possible the best alternative
routes are sub-cutaneous and/or rectal
f)  The relative potency ratio of oral morphine to rectal
morphine is 1:1
g) The relative potency ratio of oral morphine to sub-
cutaneous morphine is 1:2.
h) The relative potency ratio of oral to I/V morphine is 1:3
i) Sublingual or transdermal use of other opioids may
be an alternative to subcutaneous injection (19).
Maintenance  Dose
a) Once pain relief is satisfactory and stable ; patient can be
switched to sustained release preparations to allow 8 or 12
hourly dosing.
b)  Any breakthrough pain not associated with unusual activity
should be treated with morphine elixir or ordinary morphine
sulphate tablets at 1/6 total daily dose.
Side Effect Profile
a)  Use of lowest necessary dose with minimum side
 effects is recommended.
b)  Sedation - usually subsides within a few days.
c)   Nausea and vomiting are common  but these usually
 settles within a few days but can be prevented
 using antiemetic (e.g.metoclopramide,
 Ondansterone etc).We have used Ondesterone in
 our patients for initial week or so and later
 discontinued the antiemetic gradually.
d)  Constipation and abdominal discomfort is frequentJK SCIENCE
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side effect.Laxative like Bisacodyl should be
prescribed prophylactically. We, at our Institute, avoid
using bulk laxatives as it can aggreviate  the clinical
situation.Case report of pseudo intestinal obstruction
has been reported (20).
e) The sequelae of dry mouth is easily controlled by
good mouth  care: frequent sips of iced drinks,
salivary stimulants.etc
f) For pruritis  which in our observation is very
infrequent,oral antihistamine are recommended.
g) Bronchoconspasm,again an infrequent side effect in
our observation, may necessitate use of parentral
antihistaminic and  bronchodilator(s) and switch over
to other safer opioid such as methadone.
h)Over dose symptom(s)/sign(s) appear as
confusion,agitation, hallucinations,vivid dreams and
myoclonic jerks. Worsening  renal or hepatic function
will alter the metabolism of morphine  and may cause
accumulation and toxicity. Consider adjusting dose
downwards or increasing dose interval (21).
i) Remember that :-Pain is the best antidote of morphine.
Dependency Versus Addiction
One of the most mis-understood but much highlighted
aspect of narcotic analgesics has been  their addictive
potential. One needs to clarify the demarcation between
addiction and dependence. The dependence simply means
a patient needs the drug to prevent his distressing
symptoms secondary to the absence of the drug--a
withdrawal/an Abstinence reaction. This has medical
dimension and implications. Addiction, on the other hand
has social implications alone. Addicts devote all their
resources to the drug they must have sacrificing every
thing they value.; they give up their enjoyment of family,
food, sex and personal freedom to the drug in question—
Their main focus being procuring and taking the
drug.Cosequently, the two terms need to be separated
apart and need not to be used interchangeably. A patient
may be dependent but not an addict. It is therefore unlikely
that a cancer patient in pain will become a street addict(22).
Recent Clinical Evidence
Oxycodone controlled-release (CR) has been shown
efficacious and well tolerated as a first-line strong opioid
for the treatment of moderate-to-severe cancer-related
pain (23).In an open-label, multicenter study assessed the
efficacy & tolerability of once-daily OROS hydromorphone
therapy in patients with chronic cancer pain.
    Figure 1:-WHO Analgesic Ladder
     Step 1
         Non-opioid+/-adjuvant
         Pain persisting or increasing?
      Step 2
         Opioid for mild to moderate pain +/-non-opioid +/-adjuvant
         Pain persisting or increasing?
      Step 3
         Opioid for moderate to severe pain+/-non-opioid +/-adjuvant
        Objective: Freedom from pain
       Adjuvant Drugs for Cancer Pain
        Drugs category                                       Indications
       Non-Steroidal Anti-Inflammatory             Bone pain
                                                                        Soft tissue infiltration
                                                                        Hepatomegaly
       Steroids                                                    Raised ICT
                                                                        Soft tissue infiltration
                                        Nerve compression
                                                                        Hepatomegaly
   Anticonvulsants and Antidepressants          Nerve compression
                                                              Paraneoplastic neuropathies
      Bis-phosphonates                                     Bone pain
The OROS hydromorphone dose  titrated over 3- 21 days
to achieve effective analgesia and maintained for up to
14 days has been shown efficaious. Adverse events were
as expected &there were no clinically significant changes
in vital signs (24).In an other study to assess the effect
and tolerability of oral normal-release morphine during
the initial phase of treatment in patients with moderate-
to-severe cancer pain results in rapid and satisfactory
pain control, and is well tolerated (25).
The European Association for Palliative Care
guidelines for treatment of cancer pain recommend a
double dose (DD) of immediate-release morphine at
bedtime instead of single doses (SD) repeated every four
hours throughout the night.Where as, a  open controlled
study reported more side effects after DD than after
SD. However,  a randomized, double-blind, crossover
study indicated the two procedures to be clinically
equivalent (26).The oral “around-the clock” administration
of sustained-release strong opioids has been
recommended for the long-term treatment of patients
suffering from chronic severe pain. No relevant
differences between the different strong opioids with
respect to efficacy and tolerability exist. However,
hydromorphone and oxycodone appear to be
advantageous over morphine due to a lack of
immunosuppression. Hydromorphone has the additional
benefit of a lower risk of intoxication by accumulation of
active metabolites in patients with decreased renal
function. As a result, although morphine has beenJK SCIENCE
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regarded as the standard for the treatment of chronic
severe pain, hydromorphone and oxycodone may be
better and safer alternatives for certain patient groups
(e.g. older age, multimorbidity, cancer) (27).
Conclusion
Opioids remain one of the most effective treatment
for cancer pain. Cancer patients have unique problems
that require special consideration in the use of opioids,
including chronic nausea, poly-pharmacy; associated co-
morbid condition(s).Current guidelines recommend the
regular use of oral opioid agonists ,on WHO guidelines,
with titration of dose according to analgesia and side
effects. Lately,modified release preperations of oral
morphine have been synthesized and used by several
authors with encouraging results.These preperations are
prescribed at 12-24 hours schedules leading to a better
patient compliance. Most of patients require alternative
routes of opioid delivery before death. The sub-cutaneous
and rectal routes are simple, safe, effective and
economical in this setting particularly for patients in a
Hospice or receiving home care.
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